Compliance Rate
Compliance Rate
50.0%
Compliant submissions
1
Incompliant submissions
1
Total trials
2
My Organizations' Clinical Trials
Showing 2775 of 3499 entries
View as:
Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Phase: N/A
Priority: Normal
Start: 09/30/04
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 05/31/06
End: 12/31/10
Due: 12/31/11
Phase: N/A
Priority: Normal
Start: 06/30/97
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 10/31/03
End: 07/31/09
Due: 07/31/10
Phase: N/A
Priority: Normal
Start: 03/10/17
End: 01/13/21
Due: 01/13/22
Phase: N/A
Priority: Normal
Start: 04/30/06
End: 03/31/09
Due: 03/31/10
Phase: N/A
Priority: Normal
Start: 09/30/08
End: 02/28/17
Due: 02/28/18
Phase: N/A
Priority: Normal
Start: 01/31/99
End: 09/30/00
Due: 09/30/01
Phase: N/A
Priority: Normal
Start: 07/10/15
End: 02/13/20
Due: 02/13/21
Phase: N/A
Priority: Normal
Start: 03/31/95
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 06/30/04
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 06/30/02
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 11/03/04
End: 10/22/25
Due: 10/22/26
Phase: N/A
Priority: Normal
Start: 04/30/93
End: 01/31/02
Due: 01/31/03
Phase: N/A
Priority: Normal
Start: 02/20/20
End: 09/30/27
Due: 09/30/28
Phase: N/A
Priority: Normal
Start: 04/18/12
End: 04/23/14
Due: 04/23/15
Phase: N/A
Priority: Normal
Start: 07/31/03
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 06/02/07
End: 05/15/18
Due: 05/15/19
Phase: N/A
Priority: Normal
Start: 04/15/11
End: 12/08/11
Due: 12/08/12
Phase: N/A
Priority: Normal
Start: 04/04/16
End: 03/25/24
Due: 03/25/25
Phase: N/A
Priority: Normal
Start: 09/30/01
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 09/06/05
End: 04/11/26
Due: 04/11/27
Phase: N/A
Priority: Normal
Start: 10/31/24
End: 12/31/26
Due: 12/31/27
Phase: N/A
Priority: Normal
Start: 02/28/09
End: 08/31/10
Due: 08/31/11
Phase: N/A
Priority: Normal
Start: 05/31/06
End: 10/31/12
Due: 10/31/13